500 new jobs
Corona vaccine gave Lonza a boost
Lonza operates the largest biopharmaceutical production facility in Europe in Visp VS. In the current year alone, Lonza has invested around one billion francs in Visp, said Board Chairman Albert Baehni in an interview with the Tamedia newspapers.
The pharmaceutical company Lonza has significantly increased investments at the Visp VS site in recent years. (archive image)
In addition, Lonza is investing another half a billion francs in Stein in Aargau. In the last ten years, the company has doubled the number of employees in Visp to 5,000. In the current year alone, 500 new jobs have been added.
Lonza pays more than 400 million Swiss francs annually in wages and pension fund contributions in Visp and an average of more than 100 million Swiss francs to local third-party companies that the group needs to expand. The fact that Lonza hasn’t paid a profit tax in Valais for six years has sparked discussions in the canton.
Baehni pointed out that in addition to the many new jobs, the group also employs 250 apprentices at the Visp site. There is probably no other company in Switzerland that invests as much and creates new jobs as Lonza.
Lonza is not just any Swiss company in a peripheral region. The order for the active ingredient in Moderna’s Covid vaccine gave the company a huge boost in reputation and helped attract talent worldwide. The Lonza is very attractive for a young biochemist.
(SDA)